$106.80
0.210.20%
At close: -
$106.80
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Ligand Pharmaceuticals Stock Guidance | NASDAQ:LGND | Benzinga
Ligand Pharmaceuticals issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/27/2025 | LGND | Ligand Pharmaceuticals | FY | 2025 | $6.00 | $6.25 | $6.14 | $180.00M | $200.00M | $188.77M | Get Alert |
| 12/10/2024 | LGND | Ligand Pharmaceuticals | FY | 2024 | $5.50 | $5.70 | $5.65 | $160.00M | $165.00M | $163.41M | Get Alert |
| 12/10/2024 | LGND | Ligand Pharmaceuticals | FY | 2025 | $6.00 | $6.25 | $6.03 | $180.00M | $200.00M | $183.10M | Get Alert |
| 11/07/2024 | LGND | Ligand Pharmaceuticals | FY | 2024 | $5.50 | $5.70 | $5.39 | $160.00M | $165.00M | $156.38M | Get Alert |
| 08/06/2024 | LGND | Ligand Pharmaceuticals | FY | 2024 | $5.00 | $5.50 | $5.16 | $140.00M | $157.00M | $147.17M | Get Alert |
| 05/07/2024 | LGND | Ligand Pharmaceuticals | FY | 2024 | $4.25 | $4.75 | $4.44 | $130.00M | $142.00M | $137.68M | Get Alert |
| 02/27/2024 | LGND | Ligand Pharmaceuticals | FY | 2024 | $4.25 | $4.75 | $4.27 | $130.00M | $142.00M | $138.50M | Get Alert |
| 12/12/2023 | LGND | Ligand Pharmaceuticals | FY | 2024 | $4.25 | $4.75 | $4.17 | $130.00M | $142.00M | $138.60M | Get Alert |
| 12/12/2023 | LGND | Ligand Pharmaceuticals | FY | 2028 | $10.00 | $10.50 | — | — | — | — | Get Alert |
| 11/08/2023 | LGND | Ligand Pharmaceuticals | FY | 2023 | $5.25 | $5.40 | $5.01 | $126.00M | $129.00M | $126.50M | Get Alert |
| 09/18/2023 | LGND | Ligand Pharmaceuticals | FY | 2023 | $5.10 | $5.25 | $4.98 | $124.00M | $126.00M | $127.05M | Get Alert |
| 08/08/2023 | LGND | Ligand Pharmaceuticals | FY | 2023 | $4.85 | $5.00 | $4.63 | $124.00M | $128.00M | $131.17M | Get Alert |
| 05/04/2023 | LGND | Ligand Pharmaceuticals | FY | 2023 | $4.60 | $4.75 | $3.52 | $124.00M | $128.00M | $128.57M | Get Alert |
| 02/22/2023 | LGND | Ligand Pharmaceuticals | FY | 2023 | $3.30 | $3.45 | $3.24 | $120.00M | $124.00M | $130.58M | Get Alert |
| 12/13/2022 | LGND | Ligand Pharmaceuticals | FY | 2022 | $4.30 | $4.45 | $4.24 | $184.00M | $189.00M | $212.82M | Get Alert |
| 12/13/2022 | LGND | Ligand Pharmaceuticals | FY | 2023 | $3.10 | $3.30 | $2.99 | $118.00M | $122.00M | $136.50M | Get Alert |
| 11/07/2022 | LGND | Ligand Pharmaceuticals | FY | 2022 | $4.30 | $4.45 | $2.79 | $184.00M | $189.00M | $181.56M | Get Alert |
| 08/08/2022 | LGND | Ligand Pharmaceuticals | FY | 2022 | $2.40 | $3.00 | $2.30 | $169.00M | $188.00M | $162.86M | Get Alert |
| 05/04/2022 | LGND | Ligand Pharmaceuticals | FY | 2022 | $1.70 | $2.20 | $3.22 | $147.00M | $172.00M | $162.39M | Get Alert |
| 02/17/2022 | LGND | Ligand Pharmaceuticals | FY | 2022 | — | — | — | $147.00M | $172.00M | $189.91M | Get Alert |
| 11/09/2021 | LGND | Ligand Pharmaceuticals | FY | 2021 | $5.80 | $6.05 | $5.93 | $265.00M | $275.00M | $270.82M | Get Alert |
| 07/29/2021 | LGND | Ligand Pharmaceuticals | FY | 2021 | $5.80 | $6.05 | $6.12 | $265.00M | $275.00M | $280.44M | Get Alert |
| 05/03/2021 | LGND | Ligand Pharmaceuticals | FY | 2021 | $6.15 | $6.15 | $6.17 | $291.00M | $291.00M | $291.62M | Get Alert |
| 02/03/2021 | LGND | Ligand Pharmaceuticals | FY | 2021 | $6.15 | $6.15 | $6.09 | $291.00M | $291.00M | $289.00M | Get Alert |
| 10/30/2020 | LGND | Ligand Pharmaceuticals | FY | 2021 | $6.00 | $6.00 | $5.89 | $285.00M | $285.00M | $276.96M | Get Alert |
| 10/30/2020 | LGND | Ligand Pharmaceuticals | FY | 2020 | $3.95 | $3.95 | $3.91 | $170.00M | $170.00M | $170.22M | Get Alert |
| 10/20/2020 | LGND | Ligand Pharmaceuticals | FY | 2020 | $3.95 | $3.95 | $4.10 | $170.00M | $170.00M | $168.78M | Get Alert |
| 10/20/2020 | LGND | Ligand Pharmaceuticals | FY | 2021 | $6.00 | $6.00 | $6.50 | $285.00M | $285.00M | $248.99M | Get Alert |
| 10/20/2020 | LGND | Ligand Pharmaceuticals | FY | 2023 | — | — | — | $220.00M | $220.00M | — | Get Alert |
| 08/03/2020 | LGND | Ligand Pharmaceuticals | FY | 2020 | $4.10 | $4.10 | $3.71 | $165.00M | $165.00M | $142.45M | Get Alert |
FAQ
What is the most recent guidance for Ligand Pharmaceuticals (LGND)?
The most recent guidance for Ligand Pharmaceuticals (LGND) was reported on February 27, 2025 for the full year 2025. The company provided earnings per share guidance in the range of $6.00 to $6.25, compared to the estimated EPS of $6.14. Additionally, Ligand Pharmaceuticals forecasted revenue between $0.18B and $0.20B for the quarter.
Browse guidance and forecast on all stocks.